CAMBRIDGE, Mass. — Vedanta Biosciences said its pivotal Phase 3 trial of VE303 for preventing recurrent Clostridioides difficile infection will continue as planned following a protocol-specified interim analysis that found no safety concerns and encouraging efficacy signals.
The company said the independent Data Monitoring Committee overseeing the RESTORATiVE303 study completed its first interim review after 50 percent of enrolled participants reached the Week 8 primary endpoint. Based on an unblinded assessment of safety and efficacy data, the committee determined that the study had surpassed the predefined futility threshold and identified no significant adverse events or new safety signals.
As a result, the committee recommended that the trial proceed without changes.
Vedanta expects to complete enrollment in the second half of 2026 and plans to conduct a second interim analysis later that same period. The study is being conducted across more than 150 sites in roughly 20 countries and includes patients who have experienced at least one recurrence of C. difficile infection at baseline.
The RESTORATiVE303 trial is a randomized, double-blind, placebo-controlled global study evaluating the safety and efficacy of VE303 in patients at high risk of recurrence following antibiotic treatment for a prior infection. Participants are randomized in a 2:1 ratio to receive either a 14-day course of VE303 or a placebo, with the primary endpoint measuring recurrence rates at Week 8.
The trial population includes patients experiencing recurrent infections, including those with a first recurrence, and reflects evolving treatment standards such as the use of fidaxomicin. Vedanta intends for the results to support a future Biologics License Application submission to the U.S. Food and Drug Administration.
VE303 is an oral live biotherapeutic product designed to restore the gut microbiome and prevent recurrence. It consists of a defined consortium of eight bacterial strains developed from clonal cell banks, producing a standardized powdered drug product without relying on donor fecal material.
In a prior Phase 2 study, high-dose VE303 demonstrated a 30.5 percent adjusted absolute risk reduction in recurrence compared with placebo, corresponding to more than an 80 percent reduction in the odds of recurrence. The therapy has received Orphan Drug Designation and Fast Track Designation from the FDA.
Clostridioides difficile infection affects up to 175,000 people annually in the United States and is associated with approximately 20,000 deaths each year. Recurrence is common and increases the risk of further episodes, contributing to prolonged hospitalizations, significant morbidity, and reduced quality of life.
